Syntex produces a native chondroitin sulfate for the management of arthrosis, for injection or oral administration, low molecular weight chondroitin sulfate, and an ultra low molecular weight chondroitin sulfate triethanolamine salt for topical use which was awarded a Certificate of Suitability by the European Union.